Skip to main content

Table 1 Patients' dosimetric data

From: Hemoglobin level significantly impacts the tumor cell survival fraction in humans after internal radiotherapy

Patient Type Site number Hb (g/dL) BL time (weeks) FU time (weeks) MR D(Gy) Volume BL (ml)
1 mel. 1 10.0 −0.2 6.1 0.74 233.2   52.1 11
2     1.14 130.0   42.3 31
2 CRC 1 13.4 −6.2 8.1 0.11 169.9   79.9 58
2     4.00 6.1   8.2 17
3 CRC 1 11.1 −3.2 7.2 0.18 172.2   55.8 127
4 CRC 1 14.8 −2.3 6.2 0.15 110.9   33.1 93
2     6. 25 52.1   18.5 34
3     19.52 5.0   10.8 11
4     20.20 6.4   12.4 25
5     1.67 18.5   17.0 32
6     1.43 8.4   11.6 37
7     3.33 7.9   7.6 6
8     0.10 131.0   29.8 10
5 CRC 1 14.3 −3.5 7.2 0.05 178.5   35.2 34
2     1.75 20.4   6.1 6
6 CRC 1 13.0 −2.9 6.1 0.32 113.9   21.9 3
2     0.34 114.7   14.8 3
3     0.22 127.3   24.8 4
4     49.32 14.6   2.8 5
5     0.86 52.0   9.6 3
6     0.89 55.5   10.7 4
7 CRC 1 13.1 −0.6 6.1 1.32 52.2   10.6 37
2     2.08 26.6   6.2 36
8 mel. 1 13.4 −0.2 7.0 0.26 115.0   17.8 7
   2     0.17 147.0   21.2 6
  1. BL, baseline FDG; CRC, colorectal cancer; D, dose; FU, follow-up FDG; Hb, hemoglobin; mel., melanoma; MR, tumor metabolic ratio.